Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-3 (1999-2002)

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Matsuhisa InoueYoichi Hirakata

Abstract

Data are presented on antimicrobial resistance among isolates of Streptococcus pneumoniae, Streptoco-ccus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis collected in Japan during years 1-3 (1999-2002) of the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) surveillance study. In addition to the standard panel of PROTEKT antimicrobial agents, eight other agents often used in Japan also were tested against these isolates. The majority (30%-55%) of S. pneumoniae and H. influenzae isolates were collected from patients with community-acquired pneumonia, whereas most (>70%) S. pyogenes isolates came from patients with tonsillitis/pharyngitis. Penicillin and macrolide resistance were high among isolates of S. pneumoniae, averaging 30.9%-44.5% and 77.2%-79.9%, respectively, across all centers over the 3 study years; the highest occurrences were reported among pediatric patients aged 0-2 years. The erm(B) genotype accounted for >50% of all erythromycin-resistant isolates each study year. S. pyogenes isolates were highly susceptible to most antimicrobial agents except the macrolides and tetracycline. beta-Lactamase production among H. influenzae isolates range was 8.5%-9.7% pe...Continue Reading

References

May 1, 1995·Antimicrobial Agents and Chemotherapy·R YoshidaH Koga
Aug 18, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H SongC H Pai
Sep 20, 2002·The Journal of Antimicrobial Chemotherapy·David Felmingham
Jan 21, 2004·International Journal of Antimicrobial Agents·Matsuhisa InoueDavid Felmingham

❮ Previous
Next ❯

Citations

Mar 15, 2008·Respirology : Official Journal of the Asian Pacific Society of Respirology·Tadashi IshidaMichiaki Mishima
Nov 23, 2006·International Journal of Pediatric Otorhinolaryngology·Dewan S BillalNoboru Yamanaka
Aug 19, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Daiki OzawaYukio Katori
Jun 21, 2011·International Journal of Antimicrobial Agents·Jae-Hoon SongPo-Ren Hsueh
Jun 3, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Nobuhiro AsaiNorihiro Kaneko
Aug 19, 2009·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshiro MorikawaJunichi Mitsuyama
Jan 28, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Ryoichi SaitoNoboru Okamura
Feb 19, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ivan Fan-Ngai HungRicardo Zotomayor
Jul 17, 2018·Acta Microbiologica Et Immunologica Hungarica·Suncica PopovicNatasa Opavski
Jun 26, 2007·Respirology : Official Journal of the Asian Pacific Society of Respirology·Navneet Singh
Jul 8, 2011·Journal of Deaf Studies and Deaf Education·Joanna E CannonJennifer Beal-Alvarez
Jun 5, 2013·The Cochrane Database of Systematic Reviews·Rakesh LodhaRavindra M Pandey
Apr 15, 2009·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Maemi SohmaSachiko Satake
Nov 13, 2020·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Misuzu YahabaHidetoshi Igari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.